GSK's Votrient EU upgrade to drive sales
This article was originally published in Scrip
European authorities have upgraded the authorization for GlaxoSmithKline's Votrient (pazopanib) from conditional to full, says the firm. It looks as though the news will drive sales and uptake.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.